CC2D1A and cancer: In the present study, we show (1) patients with high CC2D1A expression in their tumor samples had shorter overall and progression free survival (Figure 2), (2) cancer cells become more sensitive to both paclitaxel and cisplatin upon stable knockdown of CC2D1A (Figures 3, 4), and (3) mice bearing CC2D1A-deficient xenografts survived longer only when treated with chemotherapeutic agents (Figure 5).